Susquehanna International Group’s Entera Bio ENTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-64,910
Closed -$126K 13389
2025
Q4
$126K Sell
64,910
-2,267
-3% -$5.32K ﹤0.01% 11314
2025
Q3
$129K Buy
67,177
+18,300
+37% +$35K ﹤0.01% 11400
2025
Q2
$92.9K Buy
48,877
+14,111
+41% +$27.9K ﹤0.01% 11839
2025
Q1
$59.1K Sell
34,766
-3,633
-9% -$7.9K ﹤0.01% 11801
2024
Q4
$80.3K Buy
38,399
+17,741
+86% +$33.1K ﹤0.01% 11468
2024
Q3
$39.3K Sell
20,658
-8,198
-28% -$14.5K ﹤0.01% 11465
2024
Q2
$53.1K Sell
28,856
-22,772
-44% -$49.8K ﹤0.01% 11388
2024
Q1
$86.2K Buy
+51,628
New +$57K ﹤0.01% 11297
2021
Q3
Sell
-66,733
Closed -$342K 12905
2021
Q2
$399K Buy
+66,733
New +$247K ﹤0.01% 10141

Other funds holding ENTX

Susquehanna International Group's ENTX Position: Q1 2026 in Review

Susquehanna International Group sold out of Entera Bio (ENTX) in Q1 2026, closing a stake of 64,910 shares — an estimated $126K sold.

Susquehanna International Group first reported a position in ENTX in Q2 2021 and held it in 9 quarters. The position peaked at $399K in Q2 2021. 26 funds tracked by Wall St. Rank hold ENTX as of Q1 2026.

  • Susquehanna International Group reported no remaining Entera Bio position as of Q1 2026 after selling out during the quarter.
  • Susquehanna International Group sold 64,910 Entera Bio shares in Q1 2026, an estimated $126K.
  • Susquehanna International Group first reported a position in Entera Bio in Q2 2021 and held it in 9 quarters.
  • Susquehanna International Group's Entera Bio position peaked at $399K in Q2 2021.
  • 26 funds tracked by Wall St. Rank held Entera Bio as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.